Healthcare Services Key Takeaways from IQVIA’s 2026 Use of Medicines Report

Research evidence excerpt

Healthcare Services Key Takeaways from IQVIA’s 2026 Use of Medicines Report

ontracting encouraged uptake.We point to recent PBM uptake of

biosimilar Humira and Stelara as a contributor going forward, with solid LoE

opportunities for both small molecules and biologics in the coming five years.

• Specialty forecasts continue to point to oncology and obesity as the primary growth

engines, with immunology, diabetes, and hematology seeing deceleration. Oncology

spending is forecast to reach $224B by 2030, with a +8% to +11% CAGR through 2030

(vs +10% over the last 5 years), driven by a continued flow of new treatments and broader

use of existing therapies, although growth is expected to slow toward +8% by 2030 as

PD-1/PD-L1 biosimilars and small molecule generics enter (with Keytruda and Opdivo

facing biosimilars beginning in late 2028). We note that IQVIA now sees both a more

stable trajectory and higher run rate for oncology spending, expecting dollar growth of

+$82B over the next five years and leveling off to an ~8% run rate exiting 2030 (vs the

prior report which forecast 5-year growth of +$62B and a 4% run-rate exiting 2029).

Immunology spending growth is expected to moderate to +4% to +7% CAGR (down

from +8% over the past 5 years), influenced by biosimilar adoption and slowing volume

uptake, with IQVIA’s outlook largely consistent with the prior report in forecasting dollar

growth of ~$25B-$30B over the next five years. Cell and gene therapy spending is

expected to more than double from $5.7B in 2025 to $12.5B by 2030 in the base case, with

a wide $8.5B-$25.0B scenario range reflecting uncertainty around uptake and

reimbursement. We see this upward revision to oncology as one of the more constructive